Landec Corporation Stock News

Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach

Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations

Lifecore, Burford, KKR, PAR, and Cellebrite are well-positioned despite trade policy and tariff headwinds, each with unique catalysts for growth. KKR stands out for its asset growth, brand strength, and resilience, benefiting from the migration to private assets and high-net-worth channels. PAR's high-margin software, resilient QSR customer base, and strong growth prospects outweigh tariff risk...

Holding a meaningful cash position due to buyouts, providing optionality and safety amidst macro uncertainty, with plans to invest opportunistically. Lifecore Biomedical shows promise with strengthened balance sheet, improved sales force, and potential sale within 3 years, offering significant upside. NextNav's GPS technology investment faces short-term stock weakness but has positive FCC devel...

CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference.

CHASKA, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Lifecore granted a restricted stock unit (“RSU”) award with respect to 45,000 shares of its common stock, an option for 210,000 shares of stock, an RSU for 170,000 shares of common stock, and...

Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore's Capabilities Across Corporate Governance, Transactional Activities, and SEC Reporting and Compliance CHASKA, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully i...

Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q3 2025 Earnings Conference Call April 3, 2025 4:30 PM ET Company Participants Stephanie Diaz - Manager, IR Paul Josephs - CEO Ryan Lake - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Michael Petusky - Barrington Research Operator Good afternoon, and thank you for joining Lifecore's Fiscal 2025 Third Quarter Earnings Call. Du...